Eli Lilly shares surge on new obesity pill data. What it means for the stock from here
Jim Cramer said Eli Lilly's new trial data has turned the obesity market into a 'one-horse race.'
Fransebas
0
7
Eli Lilly and Company, Pharmaceutical company headquarters in Alcobendas, Madrid, Spain.
Cristina Arias | Cover | Getty Images
Eli Lilly is tightening its grip on the lucrative weight-loss market as it moves into a new, more convenient phase that promises to broaden the appeal of its breakthrough drugs.
